Skip to main content

ADVERTISEMENT

Poorni M. Manohar, MD

Research Reports
04/12/2023
Poorni M. Manohar, MD
Kyle E. Bastys
Micah Tratt
Julie Gralow, MD, FACP, FASCO
Keith D. Eaton, MD, PhD
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the cost of utilizing bone-modifying agents in the treatment of patients with metastatic cancer and bone involvement at a National Cancer Institute–designated cancer center.
Manohar et al investigate the...
04/12/2023
Journal of Clinical Pathways
Research Reports
10/20/2021
Poorni M. Manohar, MD
Hannah M. Linden, MD
Josh A. Roth, PhD, MHA
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al...
10/20/2021
Journal of Clinical Pathways